Table 2.

Times between alemtuzumab courses in CARE-MS I and II patients.

	Time between courses, years
	Course 2 to course 3	Course 3 to course 4	Course 4 to course 5	Course 5 to course 6
CARE-MS I
Alemtuzumab-only group over years 3–6	n = 124	n = 42	n = 13	n = 1
Mean (SD)	2.2 (1.2)	1.8 (0.9)	1.4 (0.5)	1.0 (NE)
Median	2.0	1.5	1.2	1.0
IFN–alemtuzumab group over years 5 and 6	n = 34	n = 5	−	−
Mean (SD)	1.7 (0.7)	1.3 (0.4)	−	−
Median	1.5	1.1	−	−
CARE-MS II
Alemtuzumab-only group over years 3–6	n = 178	n = 63	n = 13	n = 4
Mean (SD)	2.3 (1.1)	1.7 (0.7)	1.3 (0.3)	1.1 (0.2)
Median	2.1	1.6	1.2	1.0
IFN–alemtuzumab group over years 5 and 6	n = 36	n = 7	−	−
Mean (SD)	1.8 (0.7)	1.2 (0.1)	−	−
Median	1.8	1.2	−	−

CARE-MS, Comparison of Alemtuzumab and Rebif^® Efficacy in Multiple Sclerosis; IFN, interferon; NE, not estimable.